Beyond the Business Plan: Managing unexpected risk in biotechnology business development

Here’s a slideshow of a talk I recently gave at the Johns Hopkins biotechnology MS/MBA program. The purpose is to illustrate the elements which are important to consider after penning your business plan, and to help position oneself to be prepared for unexpected risks.
The material is largely drawn from my book, Building Biotechnology. Go ahead [...]

Drug Patent Expirations in August 2008

Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in August 2008
*Drugs may be covered by multiple patents

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration

ADVAIR DISKUS 100/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
4,992,474
Aug 12, 2008

ADVAIR DISKUS 100/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
5,126,375
Aug 12, 2008

ADVAIR DISKUS 100/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
5,225,445
Aug 12, 2008

ADVAIR DISKUS 250/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
4,992,474
Aug 12, 2008

ADVAIR DISKUS 250/50
Glaxosmithkline
fluticasone propionate; salmeterol xinafoate
5,126,375
Aug 12, 2008

ADVAIR DISKUS 250/50
Glaxosmithkline
fluticasone propionate; [...]

Roche and Genentech’s mating dance — This isn’t the first time

Roche has floated an offer to acquire Genentech, a move which has raised a flurry of questions about the sustainability of the big Pharma business model, Genentech’s future independence, and the value of Genentech. It it worth noting, however, that Roche already bought (and sold) Genentech. Using an excerpt from Building Biotechnology to illustrate, Roche [...]

Background: The Clinical and Translational Science Awards Consortium (CTSA program)

Guest content from Christopher Starr:
After years of confusion and neglect, translational research is now becoming institutionalized.

Citing the barriers between the lab and clinic, along with the difficulties and complexities of conducting clinical research, the NIH set up a major program to advance clinical and translational research. The Clinical and Translational Science Awards consortium, or [...]

Why the market does not like Flurizan

Guest content from Nicolaj H. Nielsen, managing director of Biostrat.

A case-study on the recent licensing-deal between Myriad and Lundbeck: Information asymmetry, calculated bets and royalties in the biotech industry.
The share-price of Lundbeck has fallen with approximately 10 %, since the Danish pharmaceutical company announced an inlicensing deal with the US biotech company Myriad for a new [...]

Advertise on Biotechblog

Advertising opportunities are available on BiotechBlog. Posts are widely syndicated, ensuring a large audience for your message. For more information, see the advertising form.